Literature DB >> 11472559

Wolbachia bacteria in filarial immunity and disease.

M J Taylor1, H F Cross, L Ford, W H Makunde, G B Prasad, K Bilo.   

Abstract

Lymphatic filarial nematodes are infected with endosymbiotic Wolbachia bacteria. Lipopolysaccharide from these bacteria is the major activator of innate inflammatory responses induced directly by the parasite. Here, we propose a mechanism by which Wolbachia initiates acute inflammatory responses associated with death of parasites, leading to acute filarial lymphangitis and adverse reactions to antifilarial chemotherapy. We also speculate that repeated exposure to acute inflammatory responses and the chronic release of bacteria, results in damage to infected lymphatics and desensitization of the innate immune system. These events will result in an increased susceptibility to opportunistic infections, which cause acute dermatolymphangitis associated with lymphoedema and elephantiasis. The recognition of the contribution of endosymbiotic bacteria to filarial disease could be exploited for clinical intervention by the targeting of bacteria with antibiotics in an attempt to reduce the development of filarial pathology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472559     DOI: 10.1046/j.1365-3024.2001.00400.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  24 in total

Review 1.  Immunology of parasitic helminth infections.

Authors:  Andrew S MacDonald; Maria Ilma Araujo; Edward J Pearce
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 2.  The immune response to parasitic helminths of veterinary importance and its potential manipulation for future vaccine control strategies.

Authors:  Neil Foster; Hany M Elsheikha
Journal:  Parasitol Res       Date:  2012-05       Impact factor: 2.289

3.  Homology modeling of NAD+-dependent DNA ligase of the Wolbachia endosymbiont of Brugia malayi and its drug target potential using dispiro-cycloalkanones.

Authors:  Nidhi Shrivastava; Jeetendra K Nag; Jyoti Pandey; Rama Pati Tripathi; Priyanka Shah; Mohammad Imran Siddiqi; Shailja Misra-Bhattacharya
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

4.  Lethal LPS-independent side effects after microfilaricidal treatment in Acanthocheilonema viteae-infected rodents.

Authors:  H A Müller; H Zahner
Journal:  Parasitol Res       Date:  2005-07-05       Impact factor: 2.289

Review 5.  Immunopathology of Dirofilaria immitis infection.

Authors:  F Simón; L H Kramer; A Román; W Blasini; R Morchón; C Marcos-Atxutegi; G Grandi; C Genchi
Journal:  Vet Res Commun       Date:  2006-12-23       Impact factor: 2.459

Review 6.  Lymphatic filariasis: perspectives on lymphatic remodeling and contractile dysfunction in filarial disease pathogenesis.

Authors:  Sanjukta Chakraborty; Manokaran Gurusamy; David C Zawieja; Mariappan Muthuchamy
Journal:  Microcirculation       Date:  2013-07       Impact factor: 2.628

7.  High levels of serum thromboxane B2 are generated during human pulmonary dirofilariosis.

Authors:  R Morchón; J López-Belmonte; A Rodríguez-Barbero; F Simón
Journal:  Clin Vaccine Immunol       Date:  2006-10

8.  Adult of Dirofilaria repens in a dog with recurrent multiple subcutaneous nodular lesions.

Authors:  Elisabetta Giudice; Simona Di Pietro; Gabriella Gaglio; Luana Di Giacomo; Marilena Bazzano; Giuseppe Mazzullo
Journal:  Parasitol Res       Date:  2013-11-28       Impact factor: 2.289

9.  Removal of Wolbachia from Brugia pahangi is closely linked to worm death and fecundity but does not result in altered lymphatic lesion formation in Mongolian gerbils (Meriones unguiculatus).

Authors:  Sharon R Chirgwin; Sharon U Coleman; Kristina H Porthouse; Jena M Nowling; George A Punkosdy; Thomas R Klei
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 10.  Filariasis and lymphoedema.

Authors:  K M Pfarr; A Y Debrah; S Specht; A Hoerauf
Journal:  Parasite Immunol       Date:  2009-11       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.